Schedule a Meeting
Get a SampleAugust 2024
The global aminoglycosides market size accounted for USD 7.55 billion in 2025 and is forecasted to hit around USD 13.1 billion by 2034, representing a CAGR of 6.32% from 2025 to 2034. The Asia Pacific market size was estimated at USD 2.72 billion in 2025 and is expanding at a CAGR of 6.44% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
The global aminoglycosides market size was estimated at USD 7.1 billion in 2024 and is predicted to increase from USD 7.55 billion in 2025 to approximately USD 13.1 billion by 2034, expanding at a CAGR of 6.32% from 2025 to 2034. The growth of the market is driven by the increasing government funding in research and development activities aimed at infectious and bacterial diseases.
Artificial Intelligence AI revolutionizes the way infectious diseases can be controlled by accelerating the discovery of antibiotics. AI helps in the development of new aminoglycoside formulations. AI models such as deep learning and machine learning help in resistance prediction, pathogen detection, and drug discovery. AI-based tools improve antibiotic stewardship and detect effective compounds like antimicrobial peptides and small molecules. AI also enhances drug discovery processes by improving precision and quality control. It analyzes vast datasets of compounds to identify potential aminoglycoside candidates with high affinity for bacterial targets. Moreover, AI analyzes patient data to predict individual responses to aminoglycosides. This further reduces the risks of complications and enhances patient outcomes.
The Asia Pacific aminoglycosides market size was exhibited at USD 2.56 billion in 2024 and is projected to be worth around USD 4.78 billion by 2034, growing at a CAGR of 6.44% from 2025 to 2034.
Asia Pacific dominated the aminoglycosides market with the largest share in 2024. This is mainly due to the increased healthcare research, improved capabilities of drug manufacturing, and commercialization of novel drugs. There is a high prevalence of infectious diseases, including bacterial infections. This significantly increased the demand for aminoglycosides.
China and India play a major role in the Asia Pacific aminoglycosides market. With the growing number of cases of infectious diseases in China, there is a strong focus on developing new formulations of aminoglycosides. Moreover, the prevalence of bacterial infections is rising in India due to the growing air and water pollution. The rising prevalence of infectious diseases in livestock further creates the need for aminoglycosides.
North America is projected to witness the fastest growth during the forecast period. The growth of the market in the region is mainly attributed to the increasing prevalence of infectious diseases, including bacterial infections, due to weather changes and the emergence of antibiotic-resistant strains. The increasing awareness among people about infectious diseases and health awareness campaigns support market growth. The growing aging population and per capita healthcare spending further contribute to regional market growth.
The U.S. is a major contributor to the North American market. The country is home to some of the leading pharmaceutical companies, which are focusing on novel drug discovery and development, creating opportunities for the aminoglycosides market. The emergence of antimicrobial resistance in the U.S. further supports market growth. Resistant germs that cause infections are complex and sometimes impossible to treat, which increases the need for aminoglycosides. Moreover, the U.S. government is investing heavily in developing modern treatments for a broad range of infectious diseases, driving the growth of the aminoglycosides market.
Aminoglycosides is an antibiotic, which is applicable in the treatment of aerobic gram-negative bacilli infections. They are effective against different bacteria, including Mycobacterium tuberculosis and Staphylococci. The major healthcare application of aminoglycosides is for the management of infectious and bacterial diseases. It is also used in the treatment of acute and chronic intestinal amebiasis and as an adjunct for the treatment of hepatic coma and to treat complicated urinary tract infections. Aminoglycosides are more effective against quickly multiplying organisms, and they affect and eventually destroy bacteria through different mechanisms. They need only a short contact with bacteria to kill them. The aminoglycosides market is witnessing rapid growth due to the rising prevalence of drug-resistant bacteria. Moreover, the rising R&D activities aimed at the development of new formulations support market expansion.
| Report Coverage | Details |
| Market Size by 2034 | USD 13.1 Billion |
| Market Size in 2025 | USD 7.55 Billion |
| Market Size in 2024 | USD 7.1 Billion |
| Market Growth Rate from 2025 to 2034 | CAGR of 6.32% |
| Dominated Region | Asia Pacific |
| Fastest Growing Market | North america |
| Base Year | 2024 |
| Forecast Period | 2025 to 2034 |
| Segments Covered | Product, Route of Administration, Application and Region |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America and Middle East & Africa |
Emerging Infectious Diseases
The continuous expansion of the human population in the new geographical regions significantly increases close contact with animal species that may serve as hosts for infectious agents. This rising interaction, combined with the accelerating effect of the changing climate, has become a persistent catalyst in the emergence of infectious diseases. These diseases are caused by pathogenic microorganisms, like bacteria, viruses, parasites, or fungi, and can spread both directly and indirectly among human beings. This results in the increased demand for antimicrobial treatment, particularly aminoglycosides, which drives the growth of the market.
Nephrotoxicity Challenges
Potential side effects associated with aminoglycosides hamper the growth of the aminoglycosides market. Aminoglycosides can induce nephrotoxicity, with an increase in serum creatinine and hypoosmolar urinary results developing after some days of the treatment. They are nephrotoxic due to a small but sizable proportion of the directed dose being retained in the epithelial cells lining the S1 and S2 segments of the proximal tubules after glomerular filtration.
Next-Generation Antibiotics
The widespread emergence of multidrug-resistant and communicable bacterial strains has created an urgent need for advanced antibiotic solutions, creating immense opportunities in the aminoglycosides market. The development of next-generation aminoglycoside antibiotics, such as plazomicin, is a breakthrough in combating highly resistant gram-negative pathogens. Plazomicin, a novel aminoglycoside, functions by binding to the bacterial 30S ribosomal subunit, thereby inhibiting protein synthesis in a concentration-dependent manner. It demonstrates a broad spectrum of activity against aerobic bacteria. This innovation not only enhances treatment efficacy but also opens new avenues for drug manufacturers.
The gentamicin segment held the largest share of the aminoglycosides market in 2024. Gentamicin is used for the treatment of serious bacterial infections in various parts of the body. Gentamicin belongs to the class of medicines known as aminoglycoside antibiotics. It works by killing bacteria or preventing their growth. Gentamicin is an aminoglycoside antibiotic used to treat different types of bacterial infections, including endocarditis, bone infections, pneumonia, meningitis, pelvic inflammatory disease, urinary tract infections, and sepsis.
The tobramycin segment is expected to grow at a significant rate in the coming years. It has huge intrinsic activity against Pseudomonas aeruginosa and some gentamicin-resistant Acinetobacter baumannii and Pseudomonas aeruginosa strains. It is effective for treating external infections of the eyelid and eye caused by susceptible organisms. Tobramycin is an effective antibiotic normally used in the treatment and management of different ocular and systemic infections.
The injectable drugs segment dominated the aminoglycosides market with the largest share in 2024. Injectable aminoglycosides deliver an immediate, quick-acting therapeutic effect, which is significant in emergent conditions like narcotic overdose or cardiac arrest. They are very helpful in enhancing therapeutic effects as they can be completely absorbed as compared to medications given by other routes. Moreover, injectable aminoglycosides have proven to be highly effective in managing bacterial infections due to their enhanced safety and efficacy.
The oral segment is likely to grow at the fastest rate during the forecast period. Oral administration of medication is a cost-effective and convenient way. The primary site of drug absorption is commonly the small intestine, and the bioavailability of the drug depends on the quantity of drug absorbed across the intestinal epithelium. The oral route is usually the safest and most affordable; it is the most often used route of administration. Oral formulations are beneficial over injectable formulations, such as ease of administration and reduced side effects, which is a major factor boosting their demand.
The respiratory diseases segment held the largest share of the aminoglycosides market in 2024. This is mainly due to the increased number of cases of respiratory infections. Aminoglycosides are beneficial mostly in infections involving aerobic, Gram-negative bacteria, like Enterobacter, Acinetobacter, and Pseudomonas, which cause respiratory infections. Aminoglycosides are effective against gram-negative bacteria, which are common causes of respiratory infections like bronchitis and pneumonia.
The skin infection segment is anticipated to expand at the highest CAGR during the projection period. The growth of the segment is attributed to the rising prevalence of bacterial skin infections. Aminoglycosides are effective against a range of skin infections depending on the particular type and severity of the infection and the individual’s circumstances. Common and effective skin infection antibiotics include cephalosporins, penicillin derivatives, trimethoprim-sulfamethoxazole, and clindamycin.
By Product
By Route of Administration
By Application
By Region
For inquiries regarding discounts, bulk purchases, or customization requests, please contact us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
August 2024